Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

Bin Bing S Zhou, Michael Peyton, Biao He, Changnian Liu, Luc Girard, Eian Caudler, Yvonne Lo, Frederic Baribaud, Iwao Mikami, Noemi Reguart, Gengjie Yang, Yanlong Li, Wenqing Yao, Kris Vaddi, Adi F. Gazdar, Steven M. Friedman, David M. Jablons, Robert C. Newton, Jordan S. Fridman, John D. MinnaPeggy A. Scherle

Research output: Contribution to journalArticle

286 Citations (Scopus)

Abstract

We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.

Original languageEnglish (US)
Pages (from-to)39-50
Number of pages12
JournalCancer Cell
Volume10
Issue number1
DOIs
StatePublished - Jul 2006

Fingerprint

Neuregulin-1
Non-Small Cell Lung Carcinoma
Ligands
Pharmacology
Cell Line
Pharmaceutical Preparations
gefitinib
INCB3619

Keywords

  • SIGNALING

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. / Zhou, Bin Bing S; Peyton, Michael; He, Biao; Liu, Changnian; Girard, Luc; Caudler, Eian; Lo, Yvonne; Baribaud, Frederic; Mikami, Iwao; Reguart, Noemi; Yang, Gengjie; Li, Yanlong; Yao, Wenqing; Vaddi, Kris; Gazdar, Adi F.; Friedman, Steven M.; Jablons, David M.; Newton, Robert C.; Fridman, Jordan S.; Minna, John D.; Scherle, Peggy A.

In: Cancer Cell, Vol. 10, No. 1, 07.2006, p. 39-50.

Research output: Contribution to journalArticle

Zhou, BBS, Peyton, M, He, B, Liu, C, Girard, L, Caudler, E, Lo, Y, Baribaud, F, Mikami, I, Reguart, N, Yang, G, Li, Y, Yao, W, Vaddi, K, Gazdar, AF, Friedman, SM, Jablons, DM, Newton, RC, Fridman, JS, Minna, JD & Scherle, PA 2006, 'Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer', Cancer Cell, vol. 10, no. 1, pp. 39-50. https://doi.org/10.1016/j.ccr.2006.05.024
Zhou, Bin Bing S ; Peyton, Michael ; He, Biao ; Liu, Changnian ; Girard, Luc ; Caudler, Eian ; Lo, Yvonne ; Baribaud, Frederic ; Mikami, Iwao ; Reguart, Noemi ; Yang, Gengjie ; Li, Yanlong ; Yao, Wenqing ; Vaddi, Kris ; Gazdar, Adi F. ; Friedman, Steven M. ; Jablons, David M. ; Newton, Robert C. ; Fridman, Jordan S. ; Minna, John D. ; Scherle, Peggy A. / Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. In: Cancer Cell. 2006 ; Vol. 10, No. 1. pp. 39-50.
@article{8fd0c373f479438d8eebf6eaeb375896,
title = "Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer",
abstract = "We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.",
keywords = "SIGNALING",
author = "Zhou, {Bin Bing S} and Michael Peyton and Biao He and Changnian Liu and Luc Girard and Eian Caudler and Yvonne Lo and Frederic Baribaud and Iwao Mikami and Noemi Reguart and Gengjie Yang and Yanlong Li and Wenqing Yao and Kris Vaddi and Gazdar, {Adi F.} and Friedman, {Steven M.} and Jablons, {David M.} and Newton, {Robert C.} and Fridman, {Jordan S.} and Minna, {John D.} and Scherle, {Peggy A.}",
year = "2006",
month = "7",
doi = "10.1016/j.ccr.2006.05.024",
language = "English (US)",
volume = "10",
pages = "39--50",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

AU - Zhou, Bin Bing S

AU - Peyton, Michael

AU - He, Biao

AU - Liu, Changnian

AU - Girard, Luc

AU - Caudler, Eian

AU - Lo, Yvonne

AU - Baribaud, Frederic

AU - Mikami, Iwao

AU - Reguart, Noemi

AU - Yang, Gengjie

AU - Li, Yanlong

AU - Yao, Wenqing

AU - Vaddi, Kris

AU - Gazdar, Adi F.

AU - Friedman, Steven M.

AU - Jablons, David M.

AU - Newton, Robert C.

AU - Fridman, Jordan S.

AU - Minna, John D.

AU - Scherle, Peggy A.

PY - 2006/7

Y1 - 2006/7

N2 - We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.

AB - We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.

KW - SIGNALING

UR - http://www.scopus.com/inward/record.url?scp=33745791118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745791118&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2006.05.024

DO - 10.1016/j.ccr.2006.05.024

M3 - Article

C2 - 16843264

AN - SCOPUS:33745791118

VL - 10

SP - 39

EP - 50

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -